Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282443 | 0.92 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282207 | 0.90 | ABL1 (0.40) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282502 | 0.89 | DGAT1 (0.42) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283308 | 0.88 | PIK3CG (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282679 | 0.87 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282194 | 0.87 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283094 | 0.87 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283260 | 0.86 | ABL1 (0.42) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282845 | 0.86 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282534 | 0.86 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | claimed |
| CN-103249732-A | Bacteria topoisomerase II inhibiting 2-thylcarbamoylamino-1, 3-benzothiazol-5-yls | BIOTA EUROPE LTD | 2013-08-14 | — | — | CN | claimed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | ABL1 537/4885NPC1 1032/4885RAB9A 915/4885 |
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | ABL1 294/4885NPC1 1397/4885RAB9A 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.